Worldwide Clinical Trials to Acquire Catalyst Clinical Research
- Target: Catalyst Clinical Research
- Focus: Oncology CRO
- Closing: Q1 2026
- Leadership: Nick Dyer & Nik Morton to join Worldwide
Worldwide Clinical Trials has entered a definitive agreement to acquire oncology contract research organisation (CRO) Catalyst Clinical Research. Worldwide will acquire Catalyst for an undisclosed sum pending customary closing conditions and regulatory approvals. The transaction is expected to conclude in Q1 2026.
Leadership Integration
The transaction will see significant leadership integration. Catalyst Board chairman Nick Dyer will join Worldwide’s board of directors, while Catalyst president and CEO Nik Morton will become part of Worldwide’s executive leadership team.
Strategic Rationale: Oncology Focus and Global Reach
This acquisition aims to establish Worldwide as an oncology-focused CRO. Concurrently, the company is maintaining depth in several therapeutic areas and expanding its global reach for clinical trials.
Expanded Services and Hybrid Models
The integration will combine Catalyst’s solutions, specifically Catalyst Flex and Catalyst Oncology, with Worldwide’s existing portfolio. This combination offers customers expanded services, including:
- Full-service resourcing
- Functional service provider (FSP) resourcing
- Hybrid models
Technology and Data Efficiency
Additionally, the deal includes the adoption of complementary technology platforms and operational practices. These measures are designed to enhance data efficiency and visibility across the development lifecycle.
